Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast cancer research and treatment | 2018-02-01 | PMID 29110152
Rimawi Mothaffar F, De Angelis Carmine, Contreras Alejandro and 21 more
Genes: PTEN
